Align Technology (ALGN) Leerink Global Healthcare Conference 2026 summary

Market environment and regional performance

• North America has achieved greater market stability, with consumers adapting to ongoing volatility from tariffs and inflation, supporting steady transaction activity.

• Europe and APAC are experiencing strong double-digit growth, driven by under-penetration, digitization, and new product launches, with Europe still in early innings of market penetration.

• APAC, including China, shows robust growth, with local manufacturing and sales teams supporting market share gains despite limited reimbursement and ongoing VBP discussions.

• DSOs account for about one-third of North American revenue, with consolidation and standardization trends benefiting operational scale and efficiency.

• The supply chain remains resilient despite geopolitical challenges, with established regional hubs ensuring product availability.

Product strategy and innovation

• Recent product launches include zero refinement cases, offering doctors and patients more flexibility and reducing upfront costs, while evolving the product portfolio.

• The three-in-three product (three years, three refinements) has become the top seller, with the new zero refinement option expected to increase utilization, especially among orthos switching from wires and brackets.

• Product evolution is driven by improved technology, with over 90% of cases now using digital iTero scans, enhancing quality and efficiency.

• The portfolio approach allows doctors to choose between comprehensive unlimited, three-in-three, or zero refinement, catering to varying needs and price sensitivities.

• Workflow enhancements and new technology, such as iTero and SmileView, are integrated to support DSOs and individual practitioners in driving conversion and patient engagement.

Pricing, margins, and operational efficiency

• ASP is influenced by geographic mix and product type, with lower ASPs in emerging markets but higher gross margins on products without refinements.

• The company focuses on expanding its doctor base and increasing utilization, offering products that match diverse needs while maintaining strong gross margins.

• Recent restructuring and productivity initiatives, including equipment upgrades and cost reductions in resin and labor, are expected to drive 100 basis points of margin expansion this year.

• Scaling DirectFab manufacturing is initially less efficient but will improve as volume increases, reducing material waste and resin costs over time.

• Operational improvements include optimizing freight, logistics, and organizational structure to support ongoing margin expansion.